Biocon
FDA Proposal Set to Cut Biocon's Biosimilar Development Costs by Half: Impact on Global Healthcare Access
Nov 14, 2025 03:04 am CST
India's Biocon anticipates a 50% reduction in biosimilar development costs following the FDA's proposal to simplify clinical testing requirements. The company, which reported 25% growth in biosimilar revenue and holds significant U.S. market share for oncology medications, plans to launch 20 biosimilars by 2030 while expanding into the weight-loss drug market.
P Chidambaram Proposes Accountability System for Bengaluru Road Infrastructure Development
Oct 22, 2025 04:08 pm CST
Congress MP P Chidambaram addresses the Bengaluru road infrastructure controversy between Biocon's Kiran Mazumdar-Shaw and Deputy CM DK Shivakumar, suggesting a new accountability framework where private companies supervise public works execution rather than merely providing funds. The proposed system aims to improve infrastructure quality by holding supervising entities responsible for project outcomes.
Biocon Founder Meets Karnataka Leaders Amid Ongoing Bengaluru Infrastructure Debate
Oct 21, 2025 02:08 pm CST
Kiran Mazumdar-Shaw, Biocon founder, met with Karnataka Chief Minister Siddaramaiah and Deputy CM DK Shivakumar in Bengaluru following her vocal criticism of the city's deteriorating infrastructure. The meetings sparked public interest as they occurred amid a heated exchange between business leaders and government officials over Bengaluru's road conditions and waste management issues that impact India's premier technology hub.
DK Shivakumar vs Kiran Mazumdar-Shaw: The Battle Over Bengaluru's Crumbling Infrastructure
Oct 19, 2025 07:07 pm CST
The ongoing public dispute between Karnataka Deputy Chief Minister DK Shivakumar and Biocon Chief Kiran Mazumdar-Shaw highlights growing concerns about Bengaluru's deteriorating infrastructure. As industry leaders criticize road conditions and waste management, government officials defend their efforts while questioning the timing and motivation behind these public statements. This controversy underscores the challenges facing India's tech capital as it struggles to maintain infrastructure amid rapid growth.
Indian Pharma Largely Protected from Trump's 100% Tariffs on Imported Drugs
Sep 26, 2025 04:11 pm CST
President Trump's new 100% tariffs on imported branded pharmaceuticals may have minimal impact on India's drug industry as most major Indian pharma companies already operate manufacturing facilities in the US. With Indian exports to America primarily consisting of generic medications worth $10.5 billion annually, companies like Cipla, Dr Reddy's, and Biocon are strategically positioned to navigate these trade restrictions while stock markets respond cautiously to the announcement.
How To Fix Bengaluru's Civic Problem? Kiran Mazumdar Shaw Speaks To NDTV
Sep 25, 2025 12:49 pm CST
Bengaluru's crumbling civic infrastructure may finally receive a coordinated action plan, with Biocon founder Kiran Mazumdar Shaw urging both officials and citizens to share responsibility in cleaning up the city.
"Emergency Measures Needed": India Inc Flags Bengaluru Civic Issues
Sep 17, 2025 12:10 pm CST
Kiran Mazumdar-Shaw, executive chairperson of Biocon and a key voice of India Inc., has called for "emergency measures" to address civic issues in Bengaluru after the CEO of a trucking company announced plans to relocate from the Outer Ring Road